Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2014 02:32 ET | Source: Active Biotech

Active Biotech AB: Kallelse till extra bolagsstämma

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Styrelsen för Active Biotech AB (publ) har...
November 05, 2014 02:31 ET | Source: Active Biotech

Active Biotech stärker sin finansiella ställning: genomför nyemission om cirka 225 miljoner kronor

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, SINGAPORE, SYDAFRIKA ELLER NYA ZEELAND ELLER I NÅGON ANNAN...
November 05, 2014 02:31 ET | Source: Active Biotech

Active Biotech strengthens its financial position: rights issue of approximately SEK 225 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER...
November 05, 2014 02:30 ET | Source: Active Biotech

Active Biotech AB Delårsrapport januari - september 2014

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod · Teva har presenterat nya kliniska...
November 05, 2014 02:30 ET | Source: Active Biotech

Active Biotech AB Interim report January - September 2014

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod · Teva presented new clinical safety...
November 04, 2014 08:00 ET | Source: Active Biotech

Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial

ARPEGGIO and LEGATO-HD trials will further evaluate the effect of laquinimod in neurodegenerative diseases Jerusalem & Lund, Sweden - November 4, 2014 - Teva Pharmaceutical Industries Ltd....
November 04, 2014 08:00 ET | Source: Active Biotech

Teva och Active Biotech utvidgar det kliniska prövningsprogrammet för laquinimod med en ny studie i primärprogressiv MS och den första patienten är screenad för studien i Huntingtons sjukdom

Studierna ARPEGGIO och LEGATO-HD ska ytterligare undersöka laquinimods effekt i neurodegenerativa sjukdomar Lund, Sverige och Jerusalem, Israel den 4 november, 2014 - Active Biotech (NASDAQ OMX...
September 12, 2014 08:00 ET | Source: Active Biotech

Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting

Jerusalem & Lund, Sweden - September 12, 2014 - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced new follow-up data evaluating the...
September 12, 2014 08:00 ET | Source: Active Biotech

Teva presenterar nya kliniska säkerhetsdata från RRMS-patienter som behandlats med laquinimod under två år eller längre på konferensen ACTRIMS-ECTRIMS

Lund, Sverige och Jerusalem, Israel, den 12 september, 2014 - Active Biotech (NASDAQ OMX NORDIC: ACTI) och Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) meddelar idag nya uppföljningsdata från...
August 14, 2014 02:36 ET | Source: Active Biotech

Active Biotech's partner Teva initiates a laquinimod clinical trial in Huntington's disease

LUND, Sweden, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to...